Agenus (AGEN) RA Capital Management has filed a Schedule 13G with the SEC, disclosing a 9.99% beneficial ownership stake in Agenus. Sector: Biotechnology Key Highlights: • RA Capital owns up to 4.34 million shares (common stock + exercisable warrants) • Stake capped at 9.99% due to ownership blockers • Filing reflects a passive investment Why It Matters: RA Capital is a prominent healthcare-focused investment firm. This disclosure shows continued institutional interest in Agenus, though the passive nature and ownership cap indicate they are not seeking active control at this time. Ticker: #AGEN Focus: Institutional Ownership, Biotechnology https://www/thinksabio.com/reports/isr/#AGEN